3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
47
Melanoma
23
Neoplasm Metastasis
19
Neoplasms
18
Squamous Cell Carcinoma of Head and Neck
17
Lung Neoplasms
13
Skin Neoplasms
12
Head and Neck Neoplasms
10
Recurrence
9
Carcinoma, Renal Cell
9
Prostatic Neoplasms
8
Ovarian Neoplasms
8
Colorectal Neoplasms
8
Carcinoma, Squamous Cell
8
Breast Neoplasms
8
Urinary Bladder Neoplasms
7
Carcinoma, Merkel Cell
7
Triple Negative Breast Neoplasms
6
Colonic Neoplasms
6
Carcinoma, Basal Cell
6
Carcinoma
6
Adenocarcinoma
6
Uterine Cervical Neoplasms
5
Pancreatic Neoplasms
5
Stomach Neoplasms
4
Sarcoma
4
Multiple Myeloma
4
Mouth Neoplasms
4
Glioblastoma
4
Fallopian Tube Neoplasms
4
Interventions
pembrolizumab
2
Docetaxel
2
Cisplatin
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
taxane
1
liposomal doxorubicin
1
durvalumab
1
cemiplimab
1
atezolizumab
1
Sorafenib
1
Pemetrexed
1
Paclitaxel
1
Nivolumab
1
Irinotecan
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Drug Therapy
1
Biosimilar Pharmaceuticals
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Vaccinia
×
cemiplimab
×
Clear all
NCT06463665
2025-09-26
VIRO-25
Genelux Corporation
Phase 2
Recruiting
142 enrolled